Insmed Director’s Multi-Million Dollar Stock Sale Shakes the Market!

New insider activity at Insmed ( (INSM) ) has taken place on December 9, 2025.TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off Director Melvin Sharoky recently made headlines by selling 20,000 shares of Insmed stock, amounting to a significant transaction worth $4,100,200. Recent Updates on INSM stock In the last 24 hours, Insmed has seen significant positive developments, particularly with the coverage initiation by Rothschild & Co Redburn, which rated the stock as a Buy. The firm set a price target based on Insmed’s strong positioning in large therapy areas with limited competition. The company’s drug, Brinsupri, a first-in-class therapy for bronchiectasis, is expected to experience strong market uptake due to the lack of competitors, with peak sales projected at $12 billion, surpassing the consensus median of $10 billion. Additionally, Insmed’s price targets were raised by Mizuho and TD Cowen, reflecting optimism following Brinsupri’s approval by the European Commission and its strategic market expansion. Spark’s Take on INSM Stock According to Spark, TipRanks’ AI Analyst, INSM is a Neutral. The overall stock score reflects Insmed’s strong technical indicators and positive corporate events, such as the approval of BRINSUPRI in the EU. However, significant challenges in financial performance, particularly in profitability and cash flow, weigh heavily on the score. The balanced outlook from the earnings call and concerns about valuation further moderate the overall assessment. To see Spark’s full report on INSM stock, click here. More about Insmed YTD Price Performance: 180.99% Average Trading Volume: 2,342,143 Technical Sentiment Signal: Buy Current Market Cap: $43.51B